Gene expression signature comparison for solid tumor chemotherapy.

• DOI: 10.1200/jco.2011.29.15_suppl.e21045
• Publication Date: 2017-02-23T18:58:03Z
• Authors: R. Lai; L. Xie; X. Wu; S. Zhang; Y. Du; S. Zhao; Y. Zheng; Y. Sun; H. LI; J. Chen; Z. LI; L. Liu; X. Tang; L. Wang; Y. Wang; M. Han; C. Liu; J. Wang; H. Li; S. Liu
• Keywords: ERCC1

e21045 Background: It is unclear which one of signatures ΔCT or RQ values from gene expression respond better in chemotherapy evaluation. Improved understanding required for the comparison analysis FFPE and blood samples. Methods: 370 solid tumor consecutive samples were tested by quantitative PCR. Among all samples, 251 cases (108 lung cancer, 72 colon 44 gastric 27 breast cancer) with self-blood control enrolled thresholds set at 15-35 cycles, involved predictive biomarkers ERCC1, BRCA1, TSand RRM1. For source dataset, a P value was computed genes between specimens tumor, subgroups blood. A summary statistic to subgroup tumors target including algoriths analyzed t test, chitest X2 Pearson’s correlation coefficients. Results: Overall, RNA isolated 324 (87.6%) among tissue successfully over 1.8ng/ul per reaction. Total cancers its examined average 4.698±2.066 (ERCC1), 6.918±2.533 (BRCA1), 5.364±2.452 (RRM1), 6.355±2.459 (TS). Average 38.157±83.086 65.030±245.821 42.841±166.933 111.820±545.89 The data extracted (ΔCT/ΔΔCT(X+SD) categorized compared, statistics indicated no significant differences 4 (P>0.05), but relative observed odds repetition dispersed CV more groups difference (p<0.05), without coefficients ΔCTand cancer (P>0.05, pearson correlation), synergism based on cutoffs (ERCC1:4.3, TS:8.5, RRM1:8.0, BRCA1:6.5) subgroup, only half situation coordinate up down-regulation occured (p<0.05). Conclusions: value- signature make stable accurate resources mRNA, could contribute personality evaluation reliable than sample.